A Pilot Study of Rituximab for the Anticoagulation Resistant Manifestations of Antiphospholipid Syndrome

Part of paid clinical trials in New York, New York.

Sponsor
Hospital for Special Surgery, New York
Study ID
NCT00537290
Phase
PHASE2
Status
Completed

Conditions

  • Antiphospholipid Syndrome

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Rituximab — DRUG
    Rituximab 1000mg IV on Days 0 and 15

Study Details

RITuximab AntiphosPholipid Syndrome (RITAPS) Study is designed to evaluate whether a medication called rituximab would reduce the signs and symptoms of antiphospholipid antibody (aPL) -related certain clinical problems.

Key Dates

Start date
Sep 30, 2007
Status verified
Oct 2017
Primary completion
Jan 31, 2013
Completion
Jan 31, 2013

Study Design

Enrollment
19 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Rituximab
    All patients will receive 1000 milligrams of rituximab by intravenous infusion on Days 1 and 15.

Primary Outcome Measure

Number of Participants Experiencing Serious and Non Serious Adverse Events [ Time Frame: 52 weeks + additional 4 months if needed ]

Locations (1)

FacilityCityStateZIPSite coordinators
Barbara Volcker Center for Women and Rheumatic Disease, Hospital for Special SurgeryNew YorkNew York10021-

Find similar trials in New York, NY

By research site
Barbara Volcker Center for Women and Rheumatic Disease, Hospital for Special Surgery· New York, NY

Related Studies